Novel combination of sorafenib and biochanin-A synergistically enhances the anti-proliferative and pro-apoptotic effects on hepatocellular carcinoma cells

Sorafenib (SOR) is the first-line treatment for hepatocellular carcinoma (HCC). However, its use is hindered by the recently expressed safety concerns. One approach for reducing SOR toxicity is to use lower doses in combination with other less toxic agents. Biochanin-A (Bio-A), a promising isoflavon...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Sci Rep
Autori principali: Youssef , Mohieldin M., Tolba, Mai F., Badawy, Noha N., Liu, Andrew W., El-Ahwany, Eman, Khalifa, Amani E., Zada, Suher, Abdel-Naim, Ashraf B.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4965826/
https://ncbi.nlm.nih.gov/pubmed/27470322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep30717
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi